When miconazole/hydrocortisone is used by patients taking oral anticoagulants, the anticoagulant effect should be carefully monitored.
Severe hypersensitivity reactions, including anaphylaxis and angioedema, have been reported during treatment with miconazole/hydrocortisone and other miconazole topical formulations (See section 4.8).
If a reaction suggesting hypersensitivity or irritation should occur, the treatment should be discontinued.
Miconazole/hydrocortisone must not come into contact with the mucosa of the eyes.
Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.
As with any topical corticosteroid, caution is advised when miconazole/hydrocortisone is to be applied to extensive surface areas or under occlusive dressings including baby napkins; similarly, application to the face should be avoided.
Long term continuous topical corticosteroid therapy should be avoided. Adrenal suppression can occur even without occlusion.
Because of its corticosteroid content avoid long-term treatment with miconazole/hydrocortisone. Once the inflammatory symptoms have disappeared treatment may be continued with miconazole cream or miconazole powder (see section 4.1).
Contact should be avoided between latex products such as contraceptive diaphragms or condoms and miconazole/hydrocortisone since the constituents of miconazole/hydrocortisone may damage the latex.
Miconazole/hydrocortisone can damage certain synthetic materials. Therefore, it is recommended to wear cotton underwear if this clothing comes into contact with the affected area.
This medicine contains 2 mg/g of Benzoic acid (E210) which may cause local irritation.
This medicine also contains 0.052 mg/g of Butylhydroxyanisole (E320) which may cause local skin reactions (e.g., contact dermatitis), or irritation to the eyes and mucous membranes.
Miconazole administered systemically is known to inhibit CYP3A4/2C9, which can lead to prolonged effects of warfarin or other vitamin K antagonists. While systemic absorption is limited with topical formulations, the concomitant use of Daktacort Hydrocortisone Cream and warfarin or other vitamin K antagonists should be done with caution and the anticoagulant effect should be carefully monitored and titrated. Patients should be advised of the symptoms of bleeding events and to immediately stop treatment with miconazole and seek medical advice should they occur (see section 4.5).
If symptoms persist or get worse, or if new symptoms occur, stop use and consult a doctor.